Aquaculture Vaccines Market Size & Share 2026 - 2035

Aquaculture Vaccines Market Size

The global aquaculture vaccines market was valued at USD 434.6 million in 2025. The market is expected to grow from USD 465.1 million in 2026 to USD 942.9 million in 2035, growing at a CAGR of 8.2% during the forecast period, according to the latest report published by Global Market Insights Inc. The aquaculture vaccines market is experiencing strong growth, driven by growing aquaculture production activities globally and high demand for fish.

According to Food Outlook, in 2025, 104.7 million tonnes of aquaculture production were expected to be covered globally. Similarly, in 2022, according to the Food and Agricultural Organization, the global fisheries and aquaculture production surpassed 223.2 million tonnes, with farmed fish accounting for more than half of global seafood consumption, creating a significant need for effective disease and aquaculture healthcare management solutions.
 

Moreover, the surge in bacterial and viral outbreaks such as Vibrio infections, Aeromonas, and Infectious Salmon Anaemia Virus (ISAV) has stimulated the demand for vaccines to reduce mortality rates and improve productivity. For instance, in 2023, 62.8 million salmon died at Norwegian salmon farms, representing a mortality rate of 16.7%.  As per FAO estimates, losses to the aquaculture industry globally are estimated at about USD 6 billion annually. Also, increasing consumer preference for antibiotic-free seafood products is further encouraging fish farmers to adopt vaccination programs as an alternative to antibiotics, thereby reducing antimicrobial resistance.
 

Aquaculture vaccines are biological preparations designed to protect aquatic animals, primarily fish and crustaceans, against infectious diseases caused by bacteria, viruses, and parasites. These vaccines work by stimulating the immune system of the fish to develop resistance against specific pathogens, thereby reducing mortality rates and improving overall health and productivity in aquaculture operations. They are administered through various routes such as injection, immersion, or oral delivery, depending on the species and farming conditions. By minimizing disease outbreaks and reducing reliance on antibiotics, aquaculture vaccines play a critical role in ensuring sustainable fish farming, improving food safety, and supporting the global seafood supply chain.
 

Key players driving the growth of the aquaculture vaccines market include Merck Animal Health, Zoetis, HIPRA, Vaxxinova International, and Kyoto Biken Laboratories which offer a wide range of vaccines targeting bacterial and viral pathogens. These companies play critical roles in product innovation, farmer education, regulatory compliance, and global distribution strategies, thereby accelerating the adoption and expansion of aquaculture vaccines worldwide.
 

Between 2022 and 2024, the aquaculture vaccines market witnessed considerable growth, driven by the expansion of intensive aquaculture practices and the rising awareness among fish farmers about biosecurity. For instance, the global market was valued at about USD 355.9 million in 2022 and reached around USD 405.6 million in 2024, growing at a moderate CAGR of roughly 6.8%. This growth can be attributed to the increasing incidence of aquatic animal diseases, the shift toward sustainable aquaculture practices, and the growing preference for vaccination over antibiotics to combat antimicrobial resistance.
 

Aquaculture Vaccines Market Trends

• Expansion of fish farming in emerging markets such as Asia-Pacific and Latin America, coupled with rising investments in research and development for oral and immersion-based vaccine delivery, is creating new growth opportunities. Strategic collaborations between vaccine manufacturers and aquaculture companies are enabling faster commercialization and wider distribution of innovative vaccines.
   
• Further, a surge in demand for high-value species such as salmon, trout, and seabass, which require robust disease management, is stimulating market growth. Climate-related stressors that increase disease susceptibility in aquaculture systems are also contributing to the rising need for preventive healthcare solutions.
   
• A key trend in the aquaculture vaccines market is the shift from post‑outbreak antibiotic treatment to preventive immunization, as producers adopt vaccination to curb bacterial and viral losses while aligning with sustainability and antimicrobial‑resistance goals. This shift is supported by continuous advances in fish immunology and vaccinology, which have improved safety, efficacy, and administration of vaccines across species and production systems.
   
• Additionally, scale and intensification continue to elevate vaccine demand. FAO’s 2024 SOFIA reports that in 2022, global aquaculture hit 130.9 million tonnes. Aquaculture surpassed capture fisheries for aquatic animal production for the first time, and a small group of producing countries accounted for the majority of output trends that structurally expand the addressable market for vaccination.
   
• Mortality burden in aquaculture practices highlights the need for vaccination, with global farm mortality estimated at 10-20% in salmon and up to 60% in tilapia. This makes disease prevention essential to unit economics and to reducing antibiotic reliance in both cold‑ and warm‑water segments.
   
• Moreover, technological innovation in vaccine development is expanding options with live‑attenuated, subunit, DNA/RNA, and nano‑enabled vaccines progressing through development. Further, multivalent and species‑specific portfolios from leading suppliers support wider adoption and standardized protocols.
   
• Examples include Merck Animal Health’s AQUAVAC range for salmonids, tilapia and marine species, and Zoetis/PHARMAQ’s ALPHA JECT and ALPHA DIP series for salmon, tilapia, sea bass, pangasius and trout, streamlining protection against multiple pathogens while fitting commercial vaccination workflows, and improving adoption.
   

Aquaculture Vaccines Market Analysis

Based on the vaccine type, the global aquaculture vaccines market is segmented into inactivated vaccine, live attenuated vaccine, subunit vaccine and other vaccine types. The inactivated vaccine segment has asserted its dominance in the market by securing a significant market share of 74.3% in 2025 and is anticipated to grow at a CAGR of 8.1% over the forecast years.
 

• The dominance of inactivated vaccines can be attributed to their safety profile, ease of storage, and the broad-spectrum protection provided by inactivated vaccines against pathogens such as bacteria and viruses.
   
• Moreover, such vaccines are widely used in various aquaculture species, including salmon, tilapia, and trout farming, as they deliver consistent immune responses without the risk of reverting to virulence.
   
• Also, inactivated vaccines are available widely in multiple delivery formats, such as injectable and immersion, which provide flexibility for large-scale operations.
   
• Further, their adoption is supported by stringent regulatory standards favoring non-live formulations, rising consumer demand for antibiotic-free seafood, and the growing emphasis on biosecurity in intensive aquaculture systems.
   
• On the other hand, the live attenuated vaccines are anticipated to witness significant growth at a CAGR of 8.7%, driven by their immunogenicity and long-lasting protection compared to traditional inactivated vaccines. These vaccines mimic natural infection without causing disease, stimulating both systemic and mucosal immunity, which is critical for aquatic species exposed to waterborne pathogens.
   

Based on the route of administration, the global aquaculture vaccines market is classified into injection vaccines, oral vaccines, and immersion and spray. The injection vaccines segment accounted for the highest market revenue of USD 263.8 million in 2025 and is projected to grow at a CAGR of 8.1% during the analysis period. 
 

• The injection vaccines lead the market owing to their superior efficacy and long-lasting immunity provided by injectable formulations, which deliver precise doses directly into the fish, ensuring optimal protection against bacterial and viral pathogens. According to Springer, vaccination by intramuscular injection is preferred by fish farmers, stimulating the market demand.
   
• Their reliability in intensive farming environments, combined with compatibility with multivalent formulations, makes them the preferred choice for large-scale operations.
   
• Additionally, advancements in automated vaccination systems and ergonomic devices have streamlined administration, reducing handling stress and improving operational efficiency in hatcheries and grow-out farms.
   
• On the other hand, oral vaccines are anticipated to witness growth at a CAGR of 8.4% over the forecast period, supported by their ease of administration and suitability for mass immunization in warm-water species such as tilapia and pangasius. Oral delivery eliminates the need for manual handling, significantly reducing labor costs and stress on fish, which is particularly advantageous in large-scale cage and pond systems.
   

Based on the application, the global aquaculture vaccines market is classified into bacterial, viral, parasitic, and combined. The bacterial segment accounted for the highest market revenue of USD 213.4 million in 2025 and is projected reach USD 468.5 million by 2035.   On the other hand, the combined application segment is anticipated to witness high growth at a CAGR of 8.5% between 2026 – 2035, emerging as the fastest-growing category, stimulated by the need for comprehensive protection against multiple pathogens in a single dose. These multivalent vaccines integrate bacterial, viral, and sometimes parasitic antigens, reducing the number of handling events and minimizing stress on fish.
 

• The bacterial segment represents one of the most significant and rapidly expanding areas of application within the market, due to the widespread occurrence of bacterial pathogens in aquaculture environments.
   
• Moreover, diseases such as streptococcus, vibriosis, and furunculosis remain major threats to farmed species, causing significant mortality and economic losses. Bacterial vaccines have become a cornerstone of preventive health programs, particularly in salmon, tilapia, and trout farming, where intensive production amplifies disease risk.
   
• Also, their adoption is reinforced by global efforts to curb antibiotic use, regulatory mandates for sustainable practices, and the availability of multivalent formulations that simplify vaccination schedules while improving farm efficiency.
   

Based on the species, the global aquaculture vaccines market is classified into salmon, trout, tilapia, seabass, seabream, turbot, carp, and other species. The salmon segment accounted for the highest market revenue of USD 198.9 million in 2025. 
 

• Salmon leads the market owing to the high commercial value of Atlantic salmon and its susceptibility to multiple bacterial and viral diseases such as furunculosis, vibriosis, and infectious pancreatic necrosis.
   
• According to SalmonBusiness, Atlantic salmon production worldwide totaled 2.71 million tonnes, or 32.6% of finfish aquaculture. Also, ScienceDirect mentions that Atlantic salmon holds up to 71.4% of total salmon production globally, stimulating the market demand.
   
• Moreover, salmon farming is majorly noticed in countries such as Norway, Chile, and Scotland, where the vaccination programs are well-established and also supported by biosecurity regulations.
   
• The segment further benefits from the availability of various advanced multivalent injectable vaccines that provide protection and reduce mortality rates in high-density farming environments. Continuous innovation in vaccine formulations and automated vaccination systems further strengthens adoption in salmon aquaculture.
   
• On the other hand, carp is anticipated to witness growth at a CAGR of 8.7% over the forecast period, supported by the dominance in freshwater aquaculture across the Asia-Pacific, particularly in China and India. Carp farming faces significant challenges from bacterial infections, creating a strong demand for effective vaccination solutions.
   

Based on distribution channel, the global aquaculture vaccines market is classified into retail, e-commerce, and veterinary hospital/clinic pharmacy. The retail segment held a market share of 57.7% in 2025 and is projected to grow at a CAGR of 8% during the analysis period.
 

• Retail outlets remain the primary channel for farm procurement, serving commercial fish farms, hatcheries, and cooperatives that require on‑hand vaccine stocks, cold‑chain support, and immediate access to ancillary supplies for scheduled vaccination cycles.
   
• Moreover, dominance is driven by proximity and service intensity of brick‑and‑mortar distributors, which provide species‑specific guidance, batch scheduling, and field technician support, ensuring correct dosing, handling, and compliance with local regulations during high‑volume vaccination windows.
   
• Likewise, the e-commerce channel is anticipated to register the fastest CAGR during the forecast period, propelled by digital ordering and last-mile cold chain improvements, allowing farms to source vaccines just in time, compare SKUs and pricing, and access documentation without clinic visits.
   

Europe Aquaculture Vaccines Market

The Europe market dominated the market with a market share of 43% in 2025.
 

• Europe accounts for a high share of the global market owing to its well-developed aquaculture sector, strong regulatory emphasis on disease prevention, and early adoption of vaccination-based fish health management.
   
• Moreover, the high practice of aquaculture farming in the region further stimulates market growth. For instance, in 2023, aquaculture production in the EU was almost 1.1 million tonnes of live weight, valued at USD 5.6 billion, according to Eurostat.
   
• In addition, strict regulations limiting prophylactic antibiotic use have accelerated the shift toward vaccines as a primary disease-control strategy.
   
• Lastly, the region benefits from a well-established cold-chain distribution network, skilled veterinary and field-technician support, and the presence of leading global aquaculture vaccine manufacturers in the region.
   

Norway aquaculture vaccines market was valued at USD 75.3 million and USD 79.9 million in 2022 and 2023, respectively. The market size reached USD 90.3 million in 2025, growing from USD 84.8 million in 2024.
 

• Norway holds a leading position in the European market, driven by its status as the region’s, as well as the world’s, most important producers of farmed salmon.
   
• For instance, Norway is the world’s largest farmed salmon producer, with annual salmon production of about 1.2 million tonnes in 2023, making up a substantial portion of global supply.
   
• High-density salmon operations with strict biosecurity make vaccination indispensable to mitigate PD, IPN, and bacterial diseases.
   
• Moreover, policy‑led reduction in antibiotics further reinforces the use of vaccines as the primary disease‑prevention tool across Norway’s salmon value chain.
   

North America Aquaculture Vaccines Market

North America market accounted for USD 67.8 million in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• North America accounts for a considerable share of the global market, supported by its advanced aquaculture sector, strong regulatory oversight, and high adoption of preventive fish-health solutions.
   
• The region is characterized by intensive farming of high-value species such as Atlantic salmon, trout, and catfish. For example, in 2023, Canada’s total aquaculture production was about 145,985 tonnes, with salmon being the dominant finfish species produced. Of this, 82,729 tonnes were salmon, making it the largest contributor by both volume and value in Canadian aquaculture.
   
• Further, strict controls on antibiotic use and growing scrutiny around antimicrobial resistance have accelerated the shift toward vaccination-led disease management in the region.
   

The U.S. dominates the North America aquaculture vaccines market, showcasing strong growth potential.

• The country’s market is driven by the broad availability of species‑specific vaccines and health tools that support consistent adoption in hatcheries and commercial farms.
   
• In addition, the country benefits from well-established veterinary infrastructure, widespread use of injectable and immersion vaccines, and a strong presence of global animal health companies, enabling large-scale vaccination programs.
   

Asia Pacific Aquaculture Vaccines Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 8.7% during the analysis timeframe.
 

• The Asia Pacific region is poised for high growth in the market, driven by rising aquaculture output and disease pressure, that catalyzes vaccine demand as countries scale production and seek sustainable disease management.
   
• For instance, as per the FAO, the top seven highest-producing countries in aquaculture are all in Asia: China, Indonesia, India, Vietnam, Bangladesh, the Philippines, and the Republic of Korea. In 2022, these countries alone accounted for 86.2% of the total world production.
   
• As a result, producers are increasingly adopting vaccines as a preventive tool to reduce mortality, improve productivity, and limit antibiotic use.
   
• Growing government support for aquaculture development and improving access to fish-health services further support the region’s rapid uptake of aquaculture vaccines.
   

The China aquaculture vaccines market is estimated to grow with a significant CAGR in the Asia Pacific market.
 

• China is emerging as a strong growth market as FAO identifies China among the top producers, and continued intensification increases the need for standardized vaccination to manage bacterial/viral burdens efficiently.
   
• For instance, as per Statista, in 2023, the aquaculture production in China was the highest in the Asia-Pacific region, with over 78.3 million metric tonnes.
   
• Also, the advances in recombinant/DNA approaches and interest in mucosal vaccines align with China’s focus on large‑scale, cost‑effective immunization technologies.
   

Latin American Aquaculture Vaccines Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Tilapia dominates Brazil’s aquaculture output, making streptococcal and TiLV vaccines critical for disease prevention and productivity gains.
   
• Moreover, increasing investments in hatchery biosecurity and research and development collaborations with global vaccine manufacturers are fostering localized vaccine development for warm-water species.
   

Middle East and Africa Aquaculture Vaccines Market

Saudi Arabia market is expected to experience substantial growth in the Middle East and Africa market in 2025.
 

• Rapid growth in marine species farming, including sea bass and sea bream, is driving demand for vaccines targeting vibriosis and pasteurellosis.
   
• Also, government incentives and infrastructure development for aquaculture are creating opportunities for vaccine suppliers to establish regional partnerships.
   

Aquaculture Vaccines Market Share

The global market is consolidated, with leading animal health companies controlling a significant share while innovation thrives among specialized players. The top five companies, Merck Animal Health, Zoetis, HIPRA, Vaxxinova International, and Kyoto Biken Laboratories, collectively account for approximately 65% of the global market, leveraging extensive product portfolios, advanced vaccine technologies, and strong global distribution networks. These companies continuously invest in research and development to introduce next-generation solutions, including recombinant, DNA-based, and oral vaccines, while expanding multivalent offerings for species such as salmon, tilapia, and sea bass.
 

The market landscape is further shaped by strategic partnerships, acquisitions, and regional expansions aimed at improving biosecurity and accelerating vaccine adoption in emerging aquaculture hubs. Meanwhile, smaller regional players and niche biotech firms contribute by focusing on species-specific vaccines, immersion and spray delivery innovations, and farm-customized autogenous solutions, fostering competitive differentiation. This dynamic environment supports rapid technological progress and sustained market growth, as global aquaculture production rises, and disease prevention becomes a cornerstone of sustainable fish farming.
 

Aquaculture Vaccines Market Companies

Prominent players operating in the aquaculture vaccines industry are as mentioned below:

• Cavac
• CIBA
• HIPRA
• Kemin Industries
• Kyoritsu Seiyaku
• Kyoto Biken Laboratories
• Merck Animal Health
• Nisseiken
• Phibro Animal Health
• Tecnovax
• Vaxxinova International
• Veterquimica
• Virbac
• Zoetis
   
• Merck Animal Health

Merck Animal Health leads the global aquaculture vaccines market with a market share of ~17%, owing to its comprehensive AQUAVAC portfolio, covering salmonids, tilapia, and marine species. The company’s strength lies in its deep R&D capabilities, regulatory expertise, and global distribution network, enabling rapid deployment of multivalent and species-specific vaccines. Merck’s focus on innovation, including oral and immersion-based solutions, positions it as a dominant player driving preventive health strategies in intensive aquaculture systems.
 

• Zoetis

Zoetis, through its Pharmaq division, is a pioneer in fish health solutions, offering advanced vaccine lines such as ALPHA JECT and ALPHA DIP for salmon, tilapia, and sea bass. Its competitive edge comes from strong farmer training programs, integrated biosecurity solutions, and continuous investment in vaccine technology. Zoetis combines product innovation with robust global logistics, ensuring reliable supply and adoption across major aquaculture hubs worldwide.
 

• HIPRA

HIPRA stands out for its specialized ICTHIOVAC range, targeting key pathogens in trout, sea bass, and other species. The company’s emphasis on immersion and injectable vaccines, coupled with partnerships for oral delivery research, strengthens its position in warm-water aquaculture markets. HIPRA’s commitment to sustainability and antibiotic reduction, supported by tailored vaccination protocols and digital health tools, makes it a trusted partner for producers seeking efficient disease prevention.
 

Aquaculture Vaccines Industry News

• In August 2024, ICAR-Central Institute of Brackishwater Aquaculture (ICAR-CIBA), Chennai signed a partnership agreement with Indian Immunologicals Limited, Hyderabad, for the commercial development of CIBA vaccine “Nodavac-R” against viral nervous necrosis in finfishes. This collaboration significantly enhances CIBA's role in advancing aquaculture health solutions, contributing to both scientific innovation and economic growth within the sector.
   
• In July 2024, Merck Animal Health completed the acquisition of the aqua business of Elanco Animal Health Incorporated. The completion of this acquisition bolsters Merck Animal Health’s position in the aqua industry with a comprehensive approach to promote fish health, welfare and sustainability in aquaculture, conservation, and fisheries.
   
• In July 2024, Fischer Medical Ventures partnered with Bio Angle Vacs Sdn Bhd to introduce innovative livestock and aquaculture vaccines in India, including the STVAC nasal spray vaccine and new feed-based fish vaccines. The collaboration focused on building local production capabilities to deliver cost-effective, easy-to-administer vaccines targeting infections such as Vibrio-related diseases in fish. The partnership enhanced Fischer MV’s market position by expanding its product portfolio and strengthening its role in India’s animal health sector.
   

The aquaculture vaccines market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccine Type

• Inactivated vaccine
• Live attenuated vaccine
• Subunit vaccine
• Other vaccine types

Market, By Route of Administration

• Injection vaccines
• Oral vaccines
• Immersion and spray

Market, By Application

• Bacterial
• Viral
• Parasitic
• Combined

Market, By Species

• Salmon
• Trout
• Tilapia
• Seabass
• Seabream
• Turbot
• Carp
• Other species

Market, By Distribution Channel

• Retail
• E-commerce
• Veterinary hospital/clinic pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Norway
  • Ireland
  • Turkey
  • Denmark
• Asia Pacific
  • China
  • India
  • Indonesia
  • Philippines
  • Thailand
  • Vietnam
  • Australia
  • New Zealand 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE